Skip to Main content

Keywords

Researcher identifiers

Social networks

    Number of documents

    61

    Dr Gwenaelle GRAVIS


    MD, Head of Onco-Urology Unit,
    Institut Paoli Calmettes and Aix-Marseille University


    Journal articles61 documents

    • G. Gravis Mescam, R. Touzani, J. Pakradouni, P. Bens Soussan, P. Marino. 1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic. Annals of Oncology, Elsevier, 2021, 32, pp.S1160. ⟨10.1016/j.annonc.2021.08.1635⟩. ⟨inserm-03667002⟩
    • M-O. Grimm, M. Oya, T.K. Choueiri, M. Schmidinger, D.I. Quinn, et al.. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101. Annals of Oncology, Elsevier, 2021, 32, pp.S690-S691. ⟨10.1016/j.annonc.2021.08.061⟩. ⟨hal-03623392⟩
    • Geraldine Pignot, Rajae Touzani, Patricia Marino, Jochen Walz, Stanislas Rybikowski, et al.. Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (6SUPPL), pp.220-220. ⟨10.1200/JCO.2021.39.6_suppl.220⟩. ⟨inserm-03665171⟩
    • Michele Maio, Michael Schenker, Jacques Medioni, Slawomir Mandziuk, Margarita Majem, et al.. Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).. Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (15_suppl), pp.2571-2571. ⟨10.1200/JCO.2021.39.15_suppl.2571⟩. ⟨hal-03623326⟩
    • Gwenaelle Gravis, Aurélie Autret, Morgane Guibert-Broudic, Thomas Dubergé, Christophe Zemmour, et al.. Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET. Clinical Genitourinary Cancer, Elsevier, 2021, 19 (4), pp.346-353. ⟨10.1016/j.clgc.2021.03.004⟩. ⟨hal-03623562⟩
    • Christine Chevreau, Christophe Massard, Aude Flechon, Rémy Delva, Gwenaëlle Gravis, et al.. Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩. ⟨hal-03208728⟩
    • Arnaud Méjean, Alain Ravaud, Simon Thezenas, Christine Chevreau, Karim Bensalah, et al.. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?. European Urology, Elsevier, 2021, 80 (4), pp.417-424. ⟨10.1016/j.eururo.2021.06.009⟩. ⟨hal-03345230⟩
    • Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, Guilhem Roubaud, Yohann Loriot, et al.. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study. Clinical Genitourinary Cancer, Elsevier, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩. ⟨hal-03631553⟩
    • Geraldine Pignot, Marion Picini, Patricia Marino, Naji Salem, Stanislas Rybikowski, et al.. Feasibility and first results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (15_suppl), pp.12071-12071. ⟨10.1200/JCO.2021.39.15_suppl.12071⟩. ⟨hal-03623123⟩
    • Bernadett Szabados, Alejo Rodriguez-Vida, Ignacio Durán, Simon Crabb, Michiel van Der Heijden, et al.. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology, Elsevier, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩. ⟨hal-03623603⟩
    • T.K. Choueiri, J. Larkin, S. Pal, R.J. Motzer, B.I. Rini, et al.. Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’. ESMO Open, European Society for Medical Oncology, 2021, 6 (4), pp.100177. ⟨10.1016/j.esmoop.2021.100177⟩. ⟨hal-03623494⟩
    • Laurence Albiges, Aude Fléchon, Christine Chevreau, Delphine Topart, Gwenaëlle Gravis, et al.. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. European Journal of Cancer, Elsevier, 2021, 142, pp.102-111. ⟨10.1016/j.ejca.2020.09.030⟩. ⟨hal-03623382⟩
    • T.K. Choueiri, J. Larkin, S. Pal, R.J. Motzer, B.I. Rini, et al.. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open, European Society for Medical Oncology, 2021, 6 (3), pp.100101. ⟨10.1016/j.esmoop.2021.100101⟩. ⟨hal-03623572⟩
    • Rémi Pelloux-Prayer, Philomène Schiele, Stéphane Oudard, Gwenaëlle Gravis, François Kleinclauss, et al.. Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. Clinical Genitourinary Cancer, Elsevier, 2021, 19 (5), pp.e326-e333. ⟨10.1016/j.clgc.2021.03.022⟩. ⟨hal-03612906⟩
    • Maelle Rony, Jean-Philippe Ratone, Jochen Walz, Geraldine Pignot, Fabrice Caillol, et al.. Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review. Frontiers in Oncology, Frontiers, 2021, 11, ⟨10.3389/fonc.2021.710477⟩. ⟨hal-03623373⟩
    • Emilien Billon, Brice Chanez, Philippe Rochigneux, Laurence Albiges, Cécile Vicier, et al.. Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. Frontiers in Immunology, Frontiers, 2021, 12, ⟨10.3389/fimmu.2021.670827⟩. ⟨hal-03623028⟩
    • Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, Christine Chevreau, Nathalie Rioux-Leclercq, et al.. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales). European Journal of Cancer, Elsevier, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩. ⟨hal-03476711⟩
    • J Campagna, R Touzani, G Gravis, P Marino, J Walz, et al.. L’annonce du cancer au diagnostic de Tumeur de vessie non infiltrant le muscle modifie-t-elle la qualité de vie et l’observance des patients ? Données de la cohorte prospective française VICAN. Progrès en Urologie, Elsevier Masson, 2021, S1166-7087 (21), pp.00213-X. ⟨10.1016/j.purol.2021.08.035⟩. ⟨inserm-03462183⟩
    • Maelle Rony, Jean-Philippe Ratone, Jochen Walz, Geraldine Pignot, Fabrice Caillol, et al.. Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review. Frontiers in Oncology, Frontiers, 2021, 11, ⟨10.3389/fonc.2021.644301⟩. ⟨hal-03623317⟩
    • Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, Elsevier, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
    • Patricia Marino, Rajae Touzani, Lorène Seguin, Jean Francois Moulin, Myriam Palomares, et al.. Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care. Cancers, MDPI, 2021, 13 (6), pp.1337. ⟨10.3390/cancers13061337⟩. ⟨inserm-03462202⟩
    • François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, et al.. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, BioMed Central, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩. ⟨hal-03583277⟩
    • Sylvie Négrier, Nathalie Rioux-Leclercq, Céline Ferlay, Marine Gross-Goupil, Gwénaelle Gravis, et al.. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European Journal of Cancer, Elsevier, 2020, 129, pp.107 - 116. ⟨10.1016/j.ejca.2020.02.001⟩. ⟨hal-02552562⟩
    • Christian Pfister, Gwenaelle Gravis, Aude Fléchon, Michel Soulié, Laurent Guy, et al.. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. European Urology, Elsevier, 2020, ⟨10.1016/j.eururo.2020.08.024⟩. ⟨hal-02995530⟩
    • C. Pfister, G. Gravis, A. Flechon, M. Soulie, Laurent Guy, et al.. Essai GETUG/AFU-V05 VESPER phase III randomisée de chimiothérapie périopératoire (schéma MVAC dose-dense ou GC) dans le cancer de vessie infiltrant localisé. Résultats sur la toxicité de la chimiothérapie et la réponse histologique. Progrès en Urologie, Elsevier Masson, 2020, 30 (13), pp.715-716. ⟨10.1016/j.purol.2020.07.038⟩. ⟨hal-02995801⟩
    • Lorène Seguin, Rajae Touzani, Anne-Déborah Bouhnik, Ali Ben Charif, Patricia Marino, et al.. Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey. Cancers, MDPI, 2020, 12 (11), pp.3453. ⟨10.3390/cancers12113453⟩. ⟨inserm-03192591⟩
    • Sotheara Moeung, Christine Chevreau, Sabrina Marsili, Christophe Massart, Aude Fléchon, et al.. Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2020, 37 (7), pp.147. ⟨10.1007/s11095-020-02861-5⟩. ⟨hal-02935842⟩
    • Aline Guillot, Charlotte Joly, Philippe Barthélémy, Emeline Meriaux, Sylvie Négrier, et al.. Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical Genitourinary Cancer, Elsevier, 2019, 17 (1), pp.e38-e43. ⟨10.1016/j.clgc.2018.08.006⟩. ⟨hal-02420071⟩
    • Rajae Touzani, Julien Mancini, Jaïs Troian, Anne-Déborah Bouhnik, Olivier Cussenot, et al.. Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men. Journal of patient-reported outcomes / J Patient Rep Outcomes, [Heidelberg] : Springer International Publishing, [2017]-, 2019, 3 (1), ⟨10.1186/s41687-019-0150-1⟩. ⟨hal-02625852⟩
    • Marine Sroussi, Reza Elaidi, Aude Fléchon, Marianne Lorcet, Delphine Borchiellini, et al.. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clinical Genitourinary Cancer, Elsevier, 2019, ⟨10.1016/j.clgc.2019.11.014⟩. ⟨hal-02556645⟩
    • Ronan Flippot, Cécile Dalban, Brigitte Laguerre, Delphine Borchiellini, Gwénaelle Gravis, et al.. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. Journal of Clinical Oncology, American Society of Clinical Oncology, 2019, 37 (23), pp.2008--2016. ⟨10.1200/JCO.18.02218⟩. ⟨hal-02931819⟩
    • Sotheara Moeung, Christine Chevreau, Vianney Poinsignon, Jérôme Guitton, Bénédicte Lelièvre, et al.. Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩. ⟨hal-02481351⟩
    • Shuichi Aoki, Koetsu Inoue, Sebastian Klein, Stefan Halvorsen, Jiang Chen, et al.. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers, MDPI, 2019, 11 (4), pp.497. ⟨10.3390/cancers11040497⟩. ⟨hal-03583447⟩
    • Brice Chanez, Max Chaffanet, José Adélaide, Jeanne Thomassin, Séverine Garnier, et al.. Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer. JCO precision oncology, American Society of Clinical Oncology, 2018, pp.1-8. ⟨10.1200/po.18.00083⟩. ⟨hal-03623699⟩
    • Gwenaelle Gravis, Emilien Billon, Capucine Baldini, Christophe Massard, Werner Hilgers, et al.. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen. European Journal of Cancer, Elsevier, 2018, 104, pp.236-238. ⟨10.1016/j.ejca.2018.09.002⟩. ⟨hal-02143638⟩
    • Claudia S. E. W. Schuurhuizen, Patricia Marino, Annemarie M. J. Braamse, Laurien M. Buffart, Florence Joly, et al.. Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12), pp.1481-1488. ⟨10.6004/jnccn.2018.7069⟩. ⟨hal-02143628⟩
    • A. Mejean, A. Ravaud, S. Thezenas, S. Colas, J. -B. Beauval, et al.. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (5), pp.417-427. ⟨10.1056/NEJMoa1803675⟩. ⟨hal-02143533⟩
    • Patricia Marino, Marie Bannier, Jean-François Moulin, Gwenaëlle Gravis. The role and use of Patient Reported Outcomes in the management of cancer patients. Bulletin du Cancer, John Libbey Eurotext, 2018, 105 (6), pp.603-609. ⟨10.1016/j.bulcan.2018.02.008⟩. ⟨inserm-02096334⟩
    • G. V. Long, S. S. Tykodi, J. G. Schneider, C. Garbe, G. Gravis, et al.. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Annals of Oncology, Elsevier, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩. ⟨hal-02143540⟩
    • Gwenaëlle Gravis, Jean-Marie Boher, Yu-Hui Chen, Glenn Liu, Karim Fizazi, et al.. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology, Elsevier, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩. ⟨inserm-02092595⟩
    • G. Gravis, R. Touzani, A-D. Bouhnik, P. Marino, G. Pignot, et al.. Gender difference in cancer survivors' perceived information 5-years after diagnosis: Data from the French national study - VICAN 5. Annals of Oncology, Elsevier, 2018, 29 (8). ⟨hal-02143650⟩
    • P Lavaud, G Gravis, S Foulon, F Joly, S Oudard, et al.. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. European Urology, Elsevier, 2017, ⟨10.1016/j.eururo.2017.09.022⟩. ⟨hal-01950269⟩
    • Sotheara Moeung, Christine Chevreau, Sophie Broutin, Jérome Guitton, Bénédicte Lelièvre, et al.. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research, American Association for Cancer Research, 2017, 23 (23), pp.7171 - 7179. ⟨10.1158/1078-0432.CCR-17-1344⟩. ⟨hal-01659726⟩
    • Gwenaëlle Gravis, François Audenet, Jacques Irani, Marc-Olivier Timsit, Philippe Barthélémy, et al.. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. Cancer Treatment Reviews, WB Saunders, 2017, 55, pp.211-217. ⟨10.1016/j.ctrv.2016.09.008⟩. ⟨hal-01632557⟩
    • Christine Pasero, Gwenaëlle Gravis, Mathilde Guerin, Samuel Granjeaud, Jeanne Thomassin-Piana, et al.. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Research, American Association for Cancer Research, 2016, 76 (8), pp.2153-2165. ⟨10.1158/0008-5472.CAN-15-1965⟩. ⟨hal-03599184⟩
    • Gwenaelle Gravis, Jean-Marie Boher, Florence Joly, Michel Soulié, Laurence Albiges, et al.. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European Urology, Elsevier, 2016, 70, pp.256 - 262. ⟨10.1016/j.eururo.2015.11.005⟩. ⟨inserm-03343628⟩
    • Nadine Houédé, Laura Dupuy, Aude Fléchon, Philippe Beuzeboc, Gwenaëlle Gravis, et al.. Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma. BJU International, Wiley, 2016, 117 (3), pp.444 - 449. ⟨10.1111/bju.13054⟩. ⟨hal-01938234⟩
    • Damien Pouessel, Sylvie Chevret, Frédéric Rolland, Gwenaëlle Gravis, Lionel Geoffrois, et al.. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. European Journal of Cancer, Elsevier, 2016, 54, pp.69--74. ⟨10.1016/j.ejca.2015.11.017⟩. ⟨hal-01278607⟩
    • Nadine Houede, Philippe Beuzeboc, Sophie Gourgou, Diego Tosi, Laura Moise, et al.. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2015, 33 (7_suppl), pp.264-264. ⟨10.1200/jco.2015.33.7_suppl.264⟩. ⟨hal-03578471⟩
    • Nadine Houédé, Philippe Beuzeboc, Sophie Gourgou, Diego Tosi, Laura Moise, et al.. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer, BioMed Central, 2015, 15 (1), pp.222. ⟨10.1186/s12885-015-1257-2⟩. ⟨inserm-01264474⟩
    • A. Kramar, S. Negrier, R. Sylvester, S. Joniau, P. Mulders, et al.. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. Annals of Oncology, Elsevier, 2015, 26 (12), pp.2392-8. ⟨10.1093/annonc/mdv380⟩. ⟨hal-01913181⟩
    • Elodie Jobard, Ellen Blanc, Sylvie Négrier, Bernard Escudier, Gwenaëlle Gravis, et al.. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. British Journal of Cancer, Cancer Research UK, 2015, 113 (8), pp.1148-1157. ⟨10.1038/bjc.2015.322⟩. ⟨hal-01234309⟩
    • Karim Fizazi, Laura Faivre, François Lesaunier, Remy Delva, Gwenaëlle Gravis, et al.. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncology, Elsevier, 2015, 16 (7), pp.787 - 794. ⟨10.1016/S1470-2045(15)00011-X⟩. ⟨hal-01914904⟩
    • Romain Mathieu, Géraldine Pignot, Alexandre Ingles, Maxime Crépel, Pierre Bigot, et al.. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urologic Oncology: Seminars and Original Investigations, Elsevier, 2015, 33 (8), pp.339.e9-339.e15. ⟨10.1016/j.urolonc.2015.05.014⟩. ⟨hal-01260654⟩
    • Gwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, Florence Joly, Franck Priou, et al.. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. European Urology, Elsevier, 2015, 68 (2), pp.196 - 204. ⟨10.1016/j.eururo.2014.09.022⟩. ⟨inserm-03353959⟩
    • K. Fizazi, G. Gravis, Aude Flechon, L. Geoffrois, C. Chevreau, et al.. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Annals of Oncology, Elsevier, 2014, 25, pp.987--91. ⟨10.1093/annonc/mdu099⟩. ⟨hal-02168058⟩
    • Gwenaëlle Gravis, Patricia Marino, Florence Joly, Stéphane Oudard, Franck Priou, et al.. Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).. European Journal of Cancer, Elsevier, 2014, pp.953 - 962. ⟨10.1016/j.ejca.2013.11.034⟩. ⟨hal-01917876⟩
    • Benoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, Bart Claes, Pascal Wolter, et al.. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncologica, Taylor & Francis, 2014, 53 (1), pp.103--112. ⟨10.3109/0284186X.2013.770600⟩. ⟨hal-01064635⟩
    • Elizabeth Devilard, Franck Bladou, Olivier Ramuz, Gilles Karsenty, Jean-Philippe Dalès, et al.. FGFR1 and WT1 are markers of human prostate cancer progression.. BMC Cancer, BioMed Central, 2006, 6, pp.272. ⟨10.1186/1471-2407-6-272⟩. ⟨inserm-00121110⟩
    • Dominique Genre, C. Protière, Geneviève Macquart-Moulin, G. Gravis, Jacques Camerlo, et al.. Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles. Supportive Care in Cancer, Springer Verlag (Germany), 2002, 10 (3), pp.222-230. ⟨10.1007/s00520-001-0322-3⟩. ⟨inserm-03199677⟩
    • D. Genre, P. Viens, F. Bertucci, C Chabannon, G. Gravis, et al.. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens. Bone Marrow Transplantation, Nature Publishing Group, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩. ⟨inserm-03199676⟩